A phase I dose escalation trial of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participants with advanced HER2+solid tumors

M. Ameratunga; A. Nagrial; P. K. H. Lau; K. T. Bui; D. Sabanathan; D. M. Browning; J. Thirlway; R. J. Lutz; J. Deckert; J. O'leary; V. Ganju

doi:10.1016/j.annonc.2025.08.1505

A phase I dose escalation trial of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participants with advanced HER2+solid tumors

M. Ameratunga
, A. Nagrial
, P. K. H. Lau
, K. T. Bui
, D. Sabanathan
, D. M. Browning
, J. Thirlway
, R. J. Lutz
, J. Deckert
, J. O'leary
, V. Ganju

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Number of pages	2
Journal	Annals of Oncology
Volume	36
Issue number	Suppl 2
DOIs	https://doi.org/10.1016/j.annonc.2025.08.1505
Publication status	Published - Sept 2025

Access to Document

10.1016/j.annonc.2025.08.1505

Cite this

Ameratunga, M., Nagrial, A., Lau, P. K. H., Bui, K. T., Sabanathan, D., Browning, D. M., Thirlway, J., Lutz, R. J., Deckert, J., O'leary, J., & Ganju, V. (2025). A phase I dose escalation trial of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participants with advanced HER2+solid tumors. Annals of Oncology, 36(Suppl 2). https://doi.org/10.1016/j.annonc.2025.08.1505

@article{de4ab59d07b64ba1a37a99f034ae91f4,

title = "A phase I dose escalation trial of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participants with advanced HER2+solid tumors",

author = "M. Ameratunga and A. Nagrial and Lau, \{P. K. H.\} and Bui, \{K. T.\} and D. Sabanathan and Browning, \{D. M.\} and J. Thirlway and Lutz, \{R. J.\} and J. Deckert and J. O'leary and V. Ganju",

year = "2025",

month = sep,

doi = "10.1016/j.annonc.2025.08.1505",

language = "English",

volume = "36",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "Suppl 2",

}

TY - JOUR

T1 - A phase I dose escalation trial of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participants with advanced HER2+solid tumors

AU - Ameratunga, M.

AU - Nagrial, A.

AU - Lau, P. K. H.

AU - Bui, K. T.

AU - Sabanathan, D.

AU - Browning, D. M.

AU - Thirlway, J.

AU - Lutz, R. J.

AU - Deckert, J.

AU - O'leary, J.

AU - Ganju, V.

PY - 2025/9

Y1 - 2025/9

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:001632380700054&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/j.annonc.2025.08.1505

DO - 10.1016/j.annonc.2025.08.1505

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 36

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl 2

ER -

A phase I dose escalation trial of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participants with advanced HER2+solid tumors

Access to Document

Other files and links

Cite this